<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6435">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018030</url>
  </required_header>
  <id_info>
    <org_study_id>113203</org_study_id>
    <nct_id>NCT01018030</nct_id>
  </id_info>
  <brief_title>Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 2-week Treatment Study to Evaluate the Safety and Efficacy of Fluticasone Furoate Nasal Spray 110 Mcg in the Treatment in the Treatment of Uncomplicated Acute Rhinosinusitis in Adults and Adolescents &gt;= 12 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Estonia: State Agency of Medicines</authority>
    <authority>Spain: Agencia Española del Medicamento y Productos Sanitarios</authority>
    <authority>Germany: Land Authority for Health and Social Issues</authority>
    <authority>Poland: URZAD REJESTRACJI PRODUKTOW LECZNICZYCH, WYROBOW MEDYCZNYCH I PRODUKTOW BIOBOJCZYCH</authority>
    <authority>Ukraine: The Central Ethics Committee of Ministry of Health of Ukraine</authority>
    <authority>Russia: Federal Service of Surveillance in Healthcare and Social development of Russian federation</authority>
    <authority>Ukraine: State Pharmacological Center of Ministry of Health of Ukraine</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Germany: Bundesinstitut für Arzneimittel und Medizinprodukte</authority>
    <authority>Norway: National Health Services</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Czech: State Institute for Drug Control</authority>
    <authority>Bulgaria: Bulgarian Drug Agency (BDA)</authority>
    <authority>Europe: European Medicines Agency</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of fluticasone furoate nasal
      spray (FFNS), without the use of an antibiotic, in the treatment of adult and adolescent
      subjects who are 12 years of age and older with uncomplicated acute rhinosinusitis (ARS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - Rationale - Acute rhinosinusitis (ARS) is a condition caused by inflammation of the nose
      and the paranasal sinuses that generally lasts up to 4 weeks. Despite ARS being a
      self-limiting condition, untreated or inadequately treated sinus infection can lead to the
      development of complications. Uncomplicated ARS is a subset of ARS and is distinguished from
      the common cold by the persistence or the worsening of sinus inflammation after the usual
      period for recovery of viral infection of the nasal cavity (i.e., 10 days). Clinically the
      difference is based on the following criteria: symptoms are present at least 10 days but
      less than 4 weeks beyond the onset of upper respiratory symptoms OR symptoms worsen after 5
      days from their onset.

      In the primary care settings, ARS is often treated empirically with antibiotics although
      they are shown to provide limited benefit in the uncomplicated ARS population.
      Alternatively, the use of an intranasal corticosteroid (INS) to control symptoms of
      uncomplicated ARS is plausible based on clinically proven ability to reduce inflammation and
      mucosal swelling.

      This study is a phase II study.

        -  Objective - The objective of this study is to evaluate the safety and efficacy of two
           doses of FFNS (110 mcg once daily and 110 mcg twice daily) compared to placebo as
           monotherapy in the treatment of adult and adolescent subjects 12 years of age and older
           with uncomplicated ARS.

        -  Study Design - This is a randomized, double-blind, placebo controlled, parallel group,
           multi-centre, 2-week treatment study. The study includes a 2-week post-treatment
           follow-up period.

      Approximately 720 subjects will be randomized to one of three treatment groups for a period
      of 14 days: FFNS 110 mcg QD, FFNS 110 mcg BID, and placebo nasal spray.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2)</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The MSS was calculated as the sum of 3 individual symptom scores for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip. Daily MSS was calculated as the average of the morning (AM) and evening (PM) MSS. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline was calculated as the daily MSS averaged over the entire treatment period minus daily MSS over the baseline period (defined as the average daily MSS over the last 3 days prior to randomization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First Time to Symptom Improvement</measure>
    <time_frame>Entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptom improvement was defined as symptom scores less than or equal to 1 (i.e., mild or no symptoms) for all three major symptoms (nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip) on 2 consecutive 12-hour assessments. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in AM MSS</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the morning (AM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in AM MSS was calculated as the AM MSS averaged over the entire treatment period minus the AM MSS over the baseline period (defined as the average AM MSS over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in PM MSS</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the evening (PM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in PM MSS was calculated as the PM MSS averaged over the entire treatment period minus the PM MSS over the baseline period (defined as the average PM MSS over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the Daily Nasal Congestion/Stuffiness Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily nasal congestion/stuffiness score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the AM Nasal Congestion/Stuffiness Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM nasal congestion/stuffiness score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the PM Nasal Congestion/Stuffiness Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM nasal congestion/stuffiness score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the Daily Sinus Headache/Pressure or Facial Pain/Pressure Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily sinus headache/pressure or facial pain/pressure score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the AM Sinus Headache/Pressure or Facial Pain/Pressure Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM sinus headache/pressure or facial pain/pressure score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the PM Sinus Headache/Pressure or Facial Pain/Pressure Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM sinus headache/pressure or facial pain/pressure score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the Daily Postnasal Drip Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily postnasal drip score was calculated as the daily postnasal drip score averaged over the entire treatment period minus the daily postnasal drip score over the baseline period (defined as the average daily postnasal drip score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the AM Postnasal Drip Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM postnasal drip score was calculated as the AM postnasal drip score averaged over the entire treatment period minus the AM postnasal drip score over the baseline period (defined as the average AM postnasal drip score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Over the Entire Treatment Period in the PM Postnasal Drip Score</measure>
    <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM postnasal drip score was calculated as the PM postnasal drip score averaged over the entire treatment period minus the PM postnasal drip score over the baseline period (defined as the average PM postnasal drip score over the last 3 days prior to randomization).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Require the Use of an Antibiotic Due to the Development of Fulminant Bacterial Rhinosinusitis (FBRS)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants who required the use of an antibiotic due to the development of FBRS during the 2-week treatment period and the 2-week follow-up period were included in the analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">741</enrollment>
  <condition>Sinusitis, Acute</condition>
  <arm_group>
    <arm_group_label>FFNS 110 mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FFNS 110 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFNS 110 mcg QD</intervention_name>
    <description>Active Nasal Spray (AM) and Placebo Nasal Spray (PM)</description>
    <arm_group_label>FFNS 110 mcg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFNS 110 mcg BID</intervention_name>
    <description>Active Nasal Spray (AM) and Active Nasal Spray (PM)</description>
    <arm_group_label>FFNS 110 mcg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Nasal Spray</intervention_name>
    <description>Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)</description>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent

          2. Outpatient

          3. Age (&gt;= 18 years at Visit 1 for Russia, Ukraine, and Germany; &gt;= 12 years at Visit 2
             for all other countries)

          4. Diagnosis of uncomplicated acute rhinosinusitis

          5. Ability and willingness to comply with study procedures and restrictions.

          6. Male or eligible female - Female subjects should not be enrolled if they plan to
             become pregnant during the time of study participation; To be eligible for entry into
             the study, females of childbearing potential must commit to the consistent and
             correct use of an acceptable method of birth control.

          7. Literate

        Exclusion Criteria:

          1. Based on the investigator's clinical judgement, subject has fulminant bacterial
             rhinosinusitis during the screening period including Visits 1 and 2.

          2. A history of acute rhinosinusitis within 12 weeks prior to the current episode as
             determined by the investigator

          3. Current or a history of other sinonasal conditions (e.g., chronic or recurrent
             rhinosinusitis, non-allergic rhinitis) within 3 years prior to Visit 1 as determined
             by the investigator

          4. Symptomatic perennial or seasonal allergic rhinitis prior to ARS episode, or allergy
             to seasonal allergens likely to be present during the study period (as determined by
             documented skin prick test or in vitro blood test).

          5. Significant concomitant medical conditions

          6. Subjects with planned elective surgery, vacation or other event during the study
             period which could prevent the subject from participating in the study according to
             protocol specifications

          7. Use of antibiotics within 30 days prior to Visit 1 for sinopulmonary infections.

          8. Use of antiviral medications such as zanamivir and oseltamivir within 30 days prior
             to Visit 1

          9. Use of analgesics or antipyretics within 1 day prior to Visit 1

         10. Known hypersensitivity or allergy to corticosteroids or any excipients in the product

         11. Use of corticosteroids, defined as:

         12. Use of any other medications that may affect nasal symptoms

         13. Use of immunosuppressive medications eight weeks prior to screening and during the
             study

         14. Immunotherapy

         15. Use of any medications that significantly inhibit the cytochrome P450 subfamily
             enzyme CYP3A4, including ritonavir and ketoconazole

         16. Clinical trial/experimental medication experience

         17. Positive pregnancy test or inconclusive pregnancy test or female who is breastfeeding

         18. Affiliation with investigational site

         19. Current tobacco use

         20. Chicken pox or measles
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benesov</city>
        <zip>256 30</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>662 63</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1311 RL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <zip>N-1357</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elverum</city>
        <zip>2408</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nesttun</city>
        <zip>N-5227</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4011</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-402 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-411 21</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lidingö</city>
        <zip>SE-181 58</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
  </removed_countries>
  <reference>
    <citation>Keith PK, Dymek A, Pfaar O, Fokkens W, Yun Kirby S, Wu W, Garris C, Topors N, Lee LA. Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study. Prim Care Respir J. 2012 Sep;21(3):267-75. doi: 10.4104/pcrj.2012.00039.</citation>
    <PMID>22614920</PMID>
  </reference>
  <verification_date>April 2011</verification_date>
  <lastchanged_date>June 20, 2013</lastchanged_date>
  <firstreceived_date>November 19, 2009</firstreceived_date>
  <firstreceived_results_date>March 17, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uncomplicated acute rhinosinusitis</keyword>
  <keyword>fluticasone furoate</keyword>
  <keyword>sinusitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were randomized to a double-blind, placebo-controlled, parallel-group, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray 110 micrograms (either once or twice daily) for the treatment of uncomplicated acute rhinosinusitis in adults and adolescent participants 12 years of age and older.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Vehicle Placebo Nasal Spray administered twice daily (BD) for 14 days</description>
        </group>
        <group group_id="P2">
          <title>FFNS 110 Mcg QD</title>
          <description>Fluticasone Furoate Nasal Spray (FFNS) 110 micrograms (mcg) administered once daily (QD) in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
        </group>
        <group group_id="P3">
          <title>FFNS 110 Mcg BD</title>
          <description>FFNS 110 mcg administered BD for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
                <participants group_id="P2" count="243"/>
                <participants group_id="P3" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="227"/>
                <participants group_id="P2" count="232"/>
                <participants group_id="P3" count="239"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Vehicle Placebo Nasal Spray administered twice daily (BD) for 14 days</description>
        </group>
        <group group_id="B2">
          <title>FFNS 110 Mcg QD</title>
          <description>Fluticasone Furoate Nasal Spray (FFNS) 110 micrograms (mcg) administered once daily (QD) in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
        </group>
        <group group_id="B3">
          <title>FFNS 110 Mcg BD</title>
          <description>FFNS 110 mcg administered BD for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="245"/>
                <measurement group_id="B2" value="240"/>
                <measurement group_id="B3" value="252"/>
                <measurement group_id="B4" value="737"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Baseline Characteristics were collected in the Intent-to-Treat Population, comprised of all participants who were randomized and received at least one dose of double-blind study drug. One participant in the placebo group and three participants in the FFNS 110 mcg QD group did not receive any study treatment.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="39.1" spread="14.81"/>
                <measurement group_id="B2" value="39.7" spread="15.64"/>
                <measurement group_id="B3" value="39.0" spread="16.02"/>
                <measurement group_id="B4" value="39.3" spread="15.48"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="143"/>
                <measurement group_id="B2" value="148"/>
                <measurement group_id="B3" value="169"/>
                <measurement group_id="B4" value="460"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="102"/>
                <measurement group_id="B2" value="92"/>
                <measurement group_id="B3" value="83"/>
                <measurement group_id="B4" value="277"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="238"/>
                <measurement group_id="B2" value="234"/>
                <measurement group_id="B3" value="244"/>
                <measurement group_id="B4" value="716"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="3"/>
                <measurement group_id="B4" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other (Other than White and Black)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="5"/>
                <measurement group_id="B4" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2)</title>
        <description>The MSS was calculated as the sum of 3 individual symptom scores for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip. Daily MSS was calculated as the average of the morning (AM) and evening (PM) MSS. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline was calculated as the daily MSS averaged over the entire treatment period minus daily MSS over the baseline period (defined as the average daily MSS over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who received at least one dose of double-blind study drug. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered twice daily (BD) for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>Fluticasone Furoate Nasal Spray (FFNS) 110 micrograms (mcg) administered once daily (QD) in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="237"/>
                  <measurement group_id="O3" value="245"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2)</title>
            <description>The MSS was calculated as the sum of 3 individual symptom scores for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip. Daily MSS was calculated as the average of the morning (AM) and evening (PM) MSS. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline was calculated as the daily MSS averaged over the entire treatment period minus daily MSS over the baseline period (defined as the average daily MSS over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-2.97" spread="0.12"/>
                  <measurement group_id="O2" value="-3.36" spread="0.13"/>
                  <measurement group_id="O3" value="-3.33" spread="0.13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.386</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
            <estimate_desc>The estimation for least squares mean was adjusted for baseline value, country, allergic rhinitis status, age, and gender.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.014</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.357</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
            <estimate_desc>The estimation for least squares mean was adjusted for baseline value, country, allergic rhinitis status, age, and gender.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Time to Symptom Improvement</title>
        <description>Symptom improvement was defined as symptom scores less than or equal to 1 (i.e., mild or no symptoms) for all three major symptoms (nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip) on 2 consecutive 12-hour assessments. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe.</description>
        <time_frame>Entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="243"/>
                  <measurement group_id="O2" value="239"/>
                  <measurement group_id="O3" value="247"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>First Time to Symptom Improvement</title>
            <description>Symptom improvement was defined as symptom scores less than or equal to 1 (i.e., mild or no symptoms) for all three major symptoms (nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip) on 2 consecutive 12-hour assessments. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe.</description>
            <units>days</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8" lower_limit="1" upper_limit="14"/>
                  <measurement group_id="O2" value="7" lower_limit="1" upper_limit="14"/>
                  <measurement group_id="O3" value="7" lower_limit="1" upper_limit="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in AM MSS</title>
        <description>Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the morning (AM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in AM MSS was calculated as the AM MSS averaged over the entire treatment period minus the AM MSS over the baseline period (defined as the average AM MSS over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="241"/>
                  <measurement group_id="O2" value="235"/>
                  <measurement group_id="O3" value="244"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in AM MSS</title>
            <description>Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the morning (AM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in AM MSS was calculated as the AM MSS averaged over the entire treatment period minus the AM MSS over the baseline period (defined as the average AM MSS over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-3.1" spread="0.12"/>
                  <measurement group_id="O2" value="-3.4" spread="0.12"/>
                  <measurement group_id="O3" value="-3.3" spread="0.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in PM MSS</title>
        <description>Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the evening (PM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in PM MSS was calculated as the PM MSS averaged over the entire treatment period minus the PM MSS over the baseline period (defined as the average PM MSS over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="236"/>
                  <measurement group_id="O3" value="242"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in PM MSS</title>
            <description>Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the evening (PM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in PM MSS was calculated as the PM MSS averaged over the entire treatment period minus the PM MSS over the baseline period (defined as the average PM MSS over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-3.0" spread="0.12"/>
                  <measurement group_id="O2" value="-3.4" spread="0.12"/>
                  <measurement group_id="O3" value="-3.4" spread="0.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Nasal Congestion/Stuffiness Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily nasal congestion/stuffiness score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="237"/>
                  <measurement group_id="O3" value="245"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Nasal Congestion/Stuffiness Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily nasal congestion/stuffiness score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="0.04"/>
                  <measurement group_id="O2" value="-1.1" spread="0.04"/>
                  <measurement group_id="O3" value="-1.1" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the AM Nasal Congestion/Stuffiness Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM nasal congestion/stuffiness score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="241"/>
                  <measurement group_id="O2" value="235"/>
                  <measurement group_id="O3" value="244"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the AM Nasal Congestion/Stuffiness Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM nasal congestion/stuffiness score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="0.04"/>
                  <measurement group_id="O2" value="-1.1" spread="0.04"/>
                  <measurement group_id="O3" value="-1.1" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the PM Nasal Congestion/Stuffiness Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM nasal congestion/stuffiness score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="237"/>
                  <measurement group_id="O3" value="242"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the PM Nasal Congestion/Stuffiness Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM nasal congestion/stuffiness score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.0" spread="0.04"/>
                  <measurement group_id="O2" value="-1.1" spread="0.05"/>
                  <measurement group_id="O3" value="-1.1" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Sinus Headache/Pressure or Facial Pain/Pressure Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily sinus headache/pressure or facial pain/pressure score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="237"/>
                  <measurement group_id="O3" value="245"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Sinus Headache/Pressure or Facial Pain/Pressure Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily sinus headache/pressure or facial pain/pressure score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1" spread="0.04"/>
                  <measurement group_id="O2" value="-1.2" spread="0.05"/>
                  <measurement group_id="O3" value="-1.2" spread="0.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the AM Sinus Headache/Pressure or Facial Pain/Pressure Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM sinus headache/pressure or facial pain/pressure score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="241"/>
                  <measurement group_id="O2" value="235"/>
                  <measurement group_id="O3" value="244"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the AM Sinus Headache/Pressure or Facial Pain/Pressure Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM sinus headache/pressure or facial pain/pressure score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.2" spread="0.05"/>
                  <measurement group_id="O2" value="-1.2" spread="0.05"/>
                  <measurement group_id="O3" value="-1.2" spread="0.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the PM Sinus Headache/Pressure or Facial Pain/Pressure Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM sinus headache/pressure or facial pain/pressure score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="237"/>
                  <measurement group_id="O3" value="242"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the PM Sinus Headache/Pressure or Facial Pain/Pressure Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM sinus headache/pressure or facial pain/pressure score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1" spread="0.05"/>
                  <measurement group_id="O2" value="-1.2" spread="0.05"/>
                  <measurement group_id="O3" value="-1.2" spread="0.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Postnasal Drip Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily postnasal drip score was calculated as the daily postnasal drip score averaged over the entire treatment period minus the daily postnasal drip score over the baseline period (defined as the average daily postnasal drip score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="237"/>
                  <measurement group_id="O3" value="245"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the Daily Postnasal Drip Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily postnasal drip score was calculated as the daily postnasal drip score averaged over the entire treatment period minus the daily postnasal drip score over the baseline period (defined as the average daily postnasal drip score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="0.05"/>
                  <measurement group_id="O2" value="-1.0" spread="0.05"/>
                  <measurement group_id="O3" value="-1.0" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the AM Postnasal Drip Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM postnasal drip score was calculated as the AM postnasal drip score averaged over the entire treatment period minus the AM postnasal drip score over the baseline period (defined as the average AM postnasal drip score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="241"/>
                  <measurement group_id="O2" value="235"/>
                  <measurement group_id="O3" value="244"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the AM Postnasal Drip Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM postnasal drip score was calculated as the AM postnasal drip score averaged over the entire treatment period minus the AM postnasal drip score over the baseline period (defined as the average AM postnasal drip score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="0.05"/>
                  <measurement group_id="O2" value="-1.1" spread="0.05"/>
                  <measurement group_id="O3" value="-1.0" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Over the Entire Treatment Period in the PM Postnasal Drip Score</title>
        <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM postnasal drip score was calculated as the PM postnasal drip score averaged over the entire treatment period minus the PM postnasal drip score over the baseline period (defined as the average PM postnasal drip score over the last 3 days prior to randomization).</description>
        <time_frame>Baseline and entire treatment period (up to 2 weeks)</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population. Participants with missing diary data at baseline or post-baseline were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="242"/>
                  <measurement group_id="O2" value="236"/>
                  <measurement group_id="O3" value="242"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline Over the Entire Treatment Period in the PM Postnasal Drip Score</title>
            <description>Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM postnasal drip score was calculated as the PM postnasal drip score averaged over the entire treatment period minus the PM postnasal drip score over the baseline period (defined as the average PM postnasal drip score over the last 3 days prior to randomization).</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="0.05"/>
                  <measurement group_id="O2" value="-1.1" spread="0.05"/>
                  <measurement group_id="O3" value="-1.0" spread="0.05"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Require the Use of an Antibiotic Due to the Development of Fulminant Bacterial Rhinosinusitis (FBRS)</title>
        <description>Participants who required the use of an antibiotic due to the development of FBRS during the 2-week treatment period and the 2-week follow-up period were included in the analysis.</description>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vehicle Placebo Nasal Spray administered BD for 14 days</description>
          </group>
          <group group_id="O2">
            <title>FFNS 110 Mcg QD</title>
            <description>FFNS 110 mcg administered QD in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
          </group>
          <group group_id="O3">
            <title>FFNS 110 Mcg BD</title>
            <description>FFNS 110 mcg administered BD for 14 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="245"/>
                  <measurement group_id="O2" value="240"/>
                  <measurement group_id="O3" value="252"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Require the Use of an Antibiotic Due to the Development of Fulminant Bacterial Rhinosinusitis (FBRS)</title>
            <description>Participants who required the use of an antibiotic due to the development of FBRS during the 2-week treatment period and the 2-week follow-up period were included in the analysis.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Vehicle Placebo Nasal Spray administered twice daily (BD) for 14 days</description>
        </group>
        <group group_id="E2">
          <title>FFNS 110 Mcg QD</title>
          <description>Fluticasone Furoate Nasal Spray (FFNS) 110 micrograms (mcg) administered once daily (QD) in the morning and vehicle placebo nasal spray administered in the evening for 14 days</description>
        </group>
        <group group_id="E3">
          <title>FFNS 110 Mcg BD</title>
          <description>FFNS 110 mcg administered BD for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Otosalpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasal septum ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="240"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
